We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pembrolizumab plus Chemotherapy Combo Improves Progression- Free Survival in Metastatic TNBC.
- Authors
Stewart, Patricia
- Abstract
The article discusses role of pembrolizumab (Keytruda) plus chemotherapy to improve progression-free survival (PFS) compared with chemotherapy alone as first-line treatment of metastatic triple-negative breast cancer (TNBC). Topics discussed include information on randomized, placebo-controlled phase 3 KEYNOTE-355 clinical trials; information on separation of progression-free survival curves; and disease control rates and duration of response rate.
- Subjects
TRIPLE-negative breast cancer; CANCER chemotherapy; HEMOPHILIACS; PEMBROLIZUMAB; MEDICAL personnel
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p1
- ISSN
2164-4403
- Publication type
Article